chir-265
Small moleculeexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Apr 1, 2006 (NCT00304525)
Timeline
Indications
Studied for
Mechanism of action
BRAF inhibitor
KDR inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
Cn1c(Nc2ccc(C(F)(F)F)cc2)nc2cc(Oc3ccnc(-c4ncc(C(F)(F)F)[nH]4)c3)ccc21- Mol. weight
- 518.42 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL558752 ↗
Also known as
- chir-265
- chir-265
- chir-265
- nvp-raf265
- nvp-raf265
- raf265
- raf265
- raf265
- raf-265
- raf-265
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01352273 | Phase 1 | Jun 1, 2011 | Array BioPharma |
| NCT00304525 | Phase 2 | Apr 1, 2006 | Novartis |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Array BioPharma | For profit | 1 | 1 | 1 | 2011 |
| Novartis | For profit | 1 | 1 | 1 | 2006 |
2 organizations
Page 1 / 1